Speaker(s): 

Kathie Wu, DO, PGY4 Hematology/Oncology Fellow, Geisinger - has nothing to disclose.

Jonathan "Ryan" Lozano, PharmD, PGY2 Oncology Pharmacy Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Tristan Maiers, PharmD, BCOP, PGY2 Oncology Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe pathophysiology and disease states treatable with bone modifying agents (BMAs)
• Compare types of BMAs and the mechanisms behind their utility in oncology
• Discuss clinical considerations prior to initiation and during treatment with BMAs
• Analyze current BMA practice guidelines

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP, Rajiv Panikkar, MD, Michele Long, BSN, Jaime Weeder, NP and Christopher Kashi, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.